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H1N1 inﬂuenza causes substantial seasonal illness and
was the subtype of the 2009 inﬂuenza pandemic. Precise
measures of antigenic distance between the vaccine and
circulating virus strains help researchers design inﬂuenza
vaccines with high vaccine effectiveness. We here intro-
duce a sequence-based method to predict vaccine effec-
tiveness in humans. Historical epidemiological data show
that this sequence-based method is as predictive of
vaccine effectiveness as hemagglutination inhibition assay
data from ferret animal model studies. Interestingly, the
expected vaccine effectiveness is greater against H1N1
than H3N2, suggesting a stronger immune response
against H1N1 than H3N2. The evolution rate of hemag-
glutinin in H1N1 is also shown to be greater than that in
H3N2, presumably due to greater immune selection
pressure.
Keywords: antigenic distance/antigenic drift/inﬂuenza/
pepitope/vaccine effectiveness
Introduction
The annual trivalent vaccine for inﬂuenza contains one
H3N2 strain, one H1N1 strain and one inﬂuenza B strain.
This vaccine is currently the primary tool to prevent inﬂu-
enza infection and to control inﬂuenza epidemics. Due to the
fast evolution of the inﬂuenza virus, the components of the
inﬂuenza vaccine are changed for many ﬂu seasons. Even
though the vaccine is usually redesigned to match closely the
newly evolved inﬂuenza virus strains, there occasionally has
been a suboptimal match between vaccine and virus. Partly
for this reason, vaccine effectiveness has varied in different
years. The desire to have a vaccine with high effectiveness
makes the prediction of the circulating inﬂuenza strain for
the next inﬂuenza season a key step in vaccine design. A
goal of the World Health Organization (WHO) is to
recommend vaccine strains for the next ﬂu season that will
have the smallest antigenic distances to the dominant circu-
lating strains in the next ﬂu season, which often means using
the dominant circulating strains in the current ﬂu season as a
reference.
A variety of distance measures have been developed to
evaluate the degree of match between the vaccine strain and
the dominant circulating strain. The hemagglutinin protein
(HA) of inﬂuenza is primarily focused upon for this distance
calculation since HA is the dominant antigen for protective
human antibodies and exhibits the highest evolutionary rate
among all the inﬂuenza genes (Rambaut et al., 2008). A
widely used deﬁnition of antigenic distance is calculated
from hemagglutination inhibition (HI) data from ferret
animal model studies. To compare a pair of strains, a 2-by-2
HI titer matrix is built, and the antigenic distance is extracted
from this matrix. This distance can be further reﬁned by a
dimensional projection technique termed antigenic cartogra-
phy (Smith et al., 2004). The mathematical basis of antigenic
cartography is the dimension reduction of the shape space in
which each point represents an inﬂuenza virus strain and the
distance between a pair of points represents the antigenic dis-
tance between the corresponding strains. Note that antigenic
cartography does not yield the distance data itself, but
assesses the distance between the given vaccine strain and
dominant circulating strain by globally considering the effect
of all the strains and the antigenic distances among them. In
the original literature of antigenic cartography (Smith et al.,
2004), HI data were the input of the antigenic cartography
algorithm that obtains the ﬁnal results of distances. Antigenic
distances can also be deﬁned by the amino acid sequences of
the strains using computer-aided methods, in which the frac-
tion of substituted amino acid in the dominant HA epitope
bound by antibody is deﬁned by pepitope as a sequence-based
antigenic distance measure (Gupta et al., 2006; Deem and
Pan 2009; Pan and Deem 2009). The amino acid sequences
are downloaded from databases and processed to obtain these
distance measures. The pepitope sequence-based method has
been shown to be an effective antigenic distance measure
between two strains of H3N2 (Deem and Lee 2003; Gupta
et al., 2006; Pan and Deem 2009). To be clear, antigenic dis-
tance is a quantity that should deﬁne difference of viral
strains, as determined by the human immune system. Ferret
HI data are not the only or even the best measure of anti-
genic distances.
The vaccine effectiveness, which varies from year to year,
correlates with the antigenic distance between the vaccine
strain and the dominant circulating strain. Thus, the vaccine
effectiveness can be predicted by calculating the antigenic
distance. Such a priori estimation of the vaccine effective-
ness guides health authorities to determine the appropriate
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For H3N2 inﬂuenza, the pepitope method offers a prediction
of vaccine effectiveness that has a higher correlation coefﬁ-
cient with vaccine effectiveness in humans than do distances
derived by other methods (Gupta et al., 2006; Pan and
Deem, 2009). In this paper, we develop the pepitope method
for H1N1 inﬂuenza. In the section Materials and methods we
describe the epidemiological data used to calculate vaccine
effectiveness and the animal model or sequence data used to
calculate antigenic distance. In results we show the corre-
lation of antigenic distance with vaccine effectiveness. We
discuss the results in the section Discussion.
Materials and Methods
Identities of vaccine strains and dominant circulating strains
The vaccine strain selection by WHO in each year follows a
standard procedure. The vaccine strains are reviewed every
year and are usually changed every 2 to 3 years. We used the
H1N1 vaccine strains and H1N1 dominant circulating strains
in the epidemiological literature that provided vaccine effec-
tiveness data used in this study.
Estimation of vaccine effectiveness
The H1N1 vaccine effectiveness is gathered from epidemio-
logical literature regarding the inﬂuenza-like illness (ILI) rate
of unvaccinated (u) and vaccinated people (v). Vaccine effec-
tiveness can be described by the following deﬁnition:
Vaccineeffectiveness ¼
u   v
u
: ð1Þ
To calculate vaccine effectiveness and its standard error, we
let Nu and Nv denote the number of subjects in the unvacci-
nated and vaccinated groups, nu and nv denote the number of
illness in the unvaccinated and vaccinated groups, respect-
ively. The values and the standard errors of u, v, and vaccine
effectiveness are
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If the vaccine effectiveness is averaged from N studies,
s2
VE ¼
P
i s2
VEi=N2,w h e r esVEi is the standard error of the
ith study.
Compared to H3N2, subtype H1N1 viruses were dominant
in fewer years. Based on the proportions of samples of
H3N2, H1N1 and inﬂuenza B collected in each year during
1977–2009, widespread H1N1 circulation was observed
in approximately 10 seasons. Epidemiological studies on
vaccine effectiveness were absent for some years when
H1N1 circulated. Additionally, we used the criteria listed
below to ﬁlter all available literature.
To ensure that the vaccine effectiveness we collected from
the literature is for H1N1, the seasons and the geographic
regions of the epidemiological studies in the literature were
compared with the inﬂuenza activity information in WHO
Weekly Epidemiological Records to conﬁrm that those
regions were dominated by H1N1 in those seasons. Subjects
were restricted to 18–64-year old healthy adult humans to
avoid effects of an underdeveloped immune system in chil-
dren or of immunosenescence in senior people. If more than
one measure of vaccine effectiveness was collected for the
same season, they were averaged to minimize the statistical
noise.
In order to minimize the effect on vaccine effectiveness
from co-circulating subtypes such as H3N2, only the epide-
miological data collected in the regions and in the ﬂu
seasons in which the H1N1 subtype was dominant were
applied to calculate the vaccine effectiveness in this study.
The seasons in which the H1N1 subtype was dominant were
reported by the literature on H1N1 vaccine effectiveness.
The studies cited in Table II for the calculation of vaccine
effectiveness gave the subtype of the predominant epidemic
virus as well as of the virus sampled from the subjects with
ILI. In addition, the dominance of H1N1 subtype is also
available in the Centers for Disease Control (CDC)
Morbidity and Mortality Weekly Reports and the WHO
Weekly Epidemiological Record. For the data in Table II,
the dominance of H1N1 subtype was shown in these
references.
The vaccine effectiveness collected from various ﬂu
seasons and regions were measured with standard errors.
Biases in the vaccine effectiveness are due to the complexity
of the vaccine effectiveness measurement, including the
character of the human population studied, such as age,
immune history, and health condition; the inﬂuence of
co-circulating H3N2 inﬂuenza strains; the character of the
vaccine distributed, such as live attenuated virus vaccine,
inactivated split-virus vaccine produced by virion disassem-
bly, or subunit vaccine only containing HA and neuramini-
dase; the method of epidemiological measurement of
inﬂuenza infection, such as virus detection, conﬁrmed symp-
tomatic inﬂuenza, or ILI; the design of the experiment, such
as natural infection or experimental challenge study; and the
progression of the epidemic in the population under study.
These biases are thus inevitable with current technology.
Here, we applied the following methods to minimize biases
in the vaccine effectiveness data. Subjects in the studies were
conﬁned to 18–64 years old healthy adult humans to pre-
clude the interference of the feeble immune system in chil-
dren or in senior people, because variation in the capability
of the immune system is a determinant of the vaccine effec-
tiveness given the same pair of vaccine strain and dominant
circulating strain. Only epidemiological studies in the season
and the region in which H1N1 subtype was dominant were
used to obtain the vaccine effectiveness data. The vaccine
involved in the referred studies is an inactivated vaccine.
Other types such as cold-adapted nasal spray vaccine were
excluded. The epidemiological measurement of infection in
K.Pan et al.
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studies designed the experiment as a challenge study. We
assume that the epidemic propagates in the population in a
similar way in each season. These criteria are used to ﬁlter
the available references and to obtain vaccine effectiveness
data with minimum bias. The standard errors of the data are
presented here. These criteria reduced the number of practi-
cal references for each season. Our meta-analysis considered
50 peer-reviewed papers, all we could ﬁnd in the literature.
We list the ones that satisfy our selection criteria for each of
the years, typically 1–3 per year.
Antigenic distance measured by sequence data
Figure 1 shows the HA1 domain with ﬁve epitopes of the H1
subtype HA. As the improvement of a previous deﬁnition of
H1 epitopes (Caton et al., 1982), these ﬁve H1 epitopes are
recognized by host antibodies and are identiﬁed by mapping
the well-deﬁned epitopes in H3 HA (Wiley et al., 1981;
Macken et al., 2001) to H1 HA and using sequence entropy
to ﬁnd additional sites under selection (Deem and Pan,
2009).
The antigenic distance between the vaccine strain and the
dominant circulating strain is the input for the vaccine effec-
tiveness prediction. The fraction of mutated amino acids in
the epitope region of HA, or the P-value, is an antigenic dis-
tance measure to quantify the similarity between two strains
(Gupta et al., 2006). One P-value is calculated for each H1
epitope
P-value ¼
Numberof substitutionsintheepitope
Numberof aminoacidsintheepitope
: ð8Þ
The pepitope is deﬁned as the maximum of ﬁve P-values for
the ﬁve epitopes, and the dominant epitope is deﬁned as the
corresponding epitope. This deﬁnition, i.e. assumption, has
lead for H3N2 to vaccine effectiveness predictions that corre-
late with those observed (Gupta et al., 2006).
Another sequence-based antigenic distance measure
uses the fraction of mutated amino acid in all the ﬁve epi-
topes
pall-epitope ¼
Numberof substitutionsinallfiveepitopes
Numberof aminoacidsinallfiveepitopes
: ð9Þ
As an alternative to pepitope and pall-epitope, psequence is also
used with the deﬁnition
psequence ¼
Number of substitutions in the
HA1 domain of hemagglutinin
Total number of amino acids in the
HA1 domain of hemagglutinin
: ð10Þ
Antigenic distance measured by HI
The animal model method to determine the distance between
the vaccine strain and the dominant circulating strain
employs the HI assay to give the HI table. See Table I: Here
Hij, i, j ¼ 1, 2 are four HI titers measuring the capability of
antibody j to inhibit HA i. Note that in reality, health auth-
orities including WHO and CDC provide HI tables with at
least eight antisera to evaluate the antigenic distance between
candidate vaccine strains and dominant circulating strain.
These HI tables are mathematically equivalent to several 2  
2 HI tables each of which deﬁnes the antigenic distance
between one pair of strains in the original HI table. For each
pair of strains, we picked up four entries determined by the
identities of these two strains and the two corresponding
antisera from the original HI table. The 2   2 HI tables in
this manuscript are used to elaborate the formulae for d1 and
d2. In this context Strain 1 is the vaccine strain and Strain 2
is the dominant circulating strain. Two distance measures
have been derived from these four HI titers in the HI table
Fig. 1 HA1 domain of the H1 HA in the ribbon format (PDB code: 1RU7).
Epitope A (blue), B (red), C (cyan), D (yellow), and E (red) are space
ﬁlling. These ﬁve H1 epitopes are the analogs of the well-deﬁned H3
epitopes (Deem and Pan, 2009).
Table I. HI table with two strains and four HI titers.
Ferret antisera against Strain 1 Ferret antisera against Strain 2
Strain 1 H11 H12
Strain 2 H21 H22
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Season Vaccine strain Dominant
circulating strain
a
Vaccine
effectiveness (%)
nu Nu nv Nv Dominant
epitope
pepitope pall-epitope psequence d1 d2
1982–83 A/Brazil/11/78 A/England/333/80 37.0+12.0
1 48 118 31 121
1 A 0.083 0.0311 0.0184 0
10 1.41
10
1983–84 A/Brazil/11/78 A/Victoria/7/83 38.1+10.3
1–3 30 60 21 67
1 C 0.121 0.0497 0.0337 1.13
11–13 13.66
11,13
55 298 46 300
2
1986–87 (a) A/Taiwan/1/86 A/Taiwan/1/86 64.8+14.3
3,4 11 217 13 723
4 00 0 0 1
1986–87 (b) A/Chile/1/83 A/Taiwan/1/86 18.5+12.1
5 92 878 75 878
5 B 0.318 0.0807 0.0399 4
12,14–18 24.48
14,16–18
1988–89 A/Taiwan/1/86 A/Taiwan/1/86 43.1+10.0
3,5 119 1125 89 1126
5 00 0 0 1
1995–96 (a) A/Texas/36/91 A/Texas/36/91 60.0+27.8
6 61 2 21 0
6 00 0 0 1
1995–96 (b)* A/Singapore/6/86 A/Texas/36/91 32.2+5.8
7 99 652 57 684
7 A 0.125 0.0559 0.0307 0.86
14,19,20 2.43
14,20
176 652 149 684
7
2006–07 A/New
Caledonia/20/99
A/New
Caledonia/20/99
40.5+2.5
8 1085 230729 1221 436600
8 00 0 0 1
2007–08* A/Solomon
Islands/3/2006
A/Solomon
Islands/3/2006
62.8+12.6
9 94 262 8 60
9 00 0 0 1
Nine pairs of vaccine strains and dominant circulating strains in seven ﬂu seasons in the Northern hemisphere were collected from literature. The quantities nu, Nu, nv, Nv, pepitope, pall-epitope, psequence, d1, and d2 are
deﬁned in the section Materials and methods. Only those seasons when H1N1 virus was dominant in at least one country or region where vaccine effectiveness data were available were considered. Two different
vaccines have occasionally been adopted in different geographic regions for the same season, in which case two sets of data were added in this table. *signiﬁes that co-circulating H3N2 was also found in the same
country or region in that season; however, the interference to the ﬁnal result from H3N2 is expected to be small, and so the sets of data with a single asterisk were preserved.
aMultiple strains are circulating in each season, while each strain has a speciﬁc proportion in the virus population in a certain region and season. The strain with the greatest proportion is deﬁned as the dominant
circulating strain, which is listed in this table. The dominant circulating strains in this table were chosen based on the literature on vaccine effectiveness, which also gave the region where the effectiveness data
were collected.
Literature used in the meta-analysis: 1. (Couch et al., 1986); 2. (Keitel et al., 1988); 3. (Couch et al., 1996); 4. (Keitel et al., 1997); 5. (Edwards et al., 1994); 6. (Treanor et al., 1999); 7. (Grotto et al., 1998);
8. (Wang et al., 2009); 9. (Belongia et al., 2008); 10. (Daniels et al., 1985); 11. (Chakraverty et al., 1986); 12. (Smith et al., 1999); 13. (WHO 1984); 14. (Hay et al., 2001); 15. (WHO, 1986); 16. (Kendal et al.,
1990); 17. (Donatelli et al., 1993); 18. (Brown et al., 1998); 19. (WHO 1992); 20. (Rimmelzwaan et al., 2001).
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H11H22
H21H12
r
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Note that antigenic cartography is carried out on the asym-
metrical distance, d1 (Smith et al., 2004). When the vaccine
strain and the dominant circulating strain in one season were
not identical, we searched the literature for the HI tables
with these two strains. The d1 and d2 values were averaged if
multiple HI tables were found for one season.
Results
We performed a meta-analysis of identities of the vaccine
strains and dominant circulating strains, vaccine effectiveness,
and antigenic distances between vaccine strains and dominant
circulating strains measured with the HI assay using ferret
antisera. In one season dominated by H1N1, epidemiological
statistics in a certain region reported in literature was used to
ﬁx the values of nu, Nu, nv, Nv, and the mean and standard
error of the vaccine effectiveness. HI assay data in literature
are also used to determine antigenic distance d1 and d2
between the vaccine strain and dominant circulating strain.
Results of the meta-analysis are listed in Table II.
Sequence-based antigenic distances pepitope, pall-epitope,a n d
psequence are calculated from the sequences of the vaccine
strain and dominant circulating strain by equations 8, 9 and
10, respectively. Values of pepitope, pall-epitope,a n dpsequence in
each season dominated by H1N1 are also listed in Table II.
While the number of data points is limited, a linear
relationship exists between vaccine effectiveness and pepitope
by using least squares. Similar to the case for H3N2 inﬂu-
enza (Gupta et al., 2006), pepitope strongly correlates with
H1N1 vaccine effectiveness, with R
2 ¼ 0.68. The ﬁtted
model predicts a vaccine effectiveness of 52.7% when
pepitope ¼ 0, and vaccine effectiveness is greater than 0 when
pepitope, 0.442. In Fig. 2, the ﬁtted trend line is within one
standard error of all data points with pepitope . 0, validating
the ability of the pepitope model to predict the vaccine effec-
tiveness with only the sequences of the vaccine strain and
the dominant circulating strain.
Although statistical errors exist in the observed vaccine
effectiveness, the collected vaccine effectiveness data reject
the null hypothesis that the vaccine effectiveness is indepen-
dent of pepitope. The nine pairs of vaccine strains and domi-
nant circulating strains in Table II have ﬁve difference
antigenic distances between vaccine strain and dominant cir-
culating strain deﬁned by pepitope. The nine pairs of strains
were thus categorized into groups 1–5 with pepitope equal to
0, 0.083, 0.121, 0.125, and 0.318, respectively, and the
average vaccine effectiveness and standard error were calcu-
lated for each group. The vaccine effectiveness differences
between these ﬁve groups were signiﬁcant, such as groups
1 and 4 (P ¼ 0.0079) and groups 1 and 5 (P ¼ 0.0054).
Moreover, statistical analysis shows that the introduction of
pepitope is valuable in the selection process of vaccine strains.
The slope of the ﬁt line is signiﬁcantly smaller than 0 (P ¼
0.0027). Hence the linear model is able to predict the
vaccine effectiveness with the knowledge of pepitope. In other
words the non-zero slope of vaccine effectiveness as a func-
tion of pepitope is signiﬁcant at the level of 0.27%.
Two other sequence-based antigenic distance measures
alternative to pepitope are pall-epitope and psequence. Unlike
pepitope, which focuses upon the mutations in the antibody
binding regions, pall-epitope calculates the fraction of mutated
amino acids in all the ﬁve epitopes, and psequence calculates
the fraction of mutated amino acids in the whole HA1
domain of HA. The psequence measure is also one of the
optional distance measures for phylogenetic softwares. In
Fig. 3, the correlation between H1N1 vaccine effectiveness
and pall-epitope has R
2 ¼ 0.70. In Fig. 4, the correlation
between H1N1 vaccine effectiveness and psequence has R
2 ¼
0.66. The predicted 54% vaccine effectiveness when
pall-epitope ¼ 0 in Fig. 3 and when psequence ¼ 0 in Fig. 4 are
almost the same as the 53% predicted by the pepitope method.
By contrast pall-epitope and psequence for H3N2 have less
impressive correlations with H3N2 vaccine effectiveness
(Gupta et al., 2006; Sun et al., 2006), and pall-epitope and
psequence are not as effective as pepitope as antigenic distance
measures and vaccine effectiveness predictors for H3N2.
Fig. 2 Vaccine effectiveness for ILI correlates with pepitope, R
2 ¼ 0.68 (solid
line). Data from Table II. The trend line quantiﬁes vaccine effectiveness as a
decreasing linear function of pepitope. Vaccine effectiveness ¼ –1.19
pepitopeþ0.53. Also shown is the vaccine effectiveness to H3N2 (dashed
line) (Gupta et al. 2006).
Fig. 3 Vaccine effectiveness for ILI correlates with pall-epitope with R
2 ¼
0.70. Data from Table II. The trend line quantiﬁes vaccine effectiveness as a
decreasing linear function of pall-epitope. Vaccine effectiveness ¼ –4.16
pall-epitopeþ0.54.
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still the most widely used measures by researchers and
health authorities to identify newly collected circulating
strains. These methods are used to recommend the vaccine
strain for the coming ﬂu season (Cox et al., 2003, 2007;
WHO Collaborating Center for Surveillance and Control of
Inﬂuenza, 2008), to draw the antigenic map (Smith et al.,
2004), and to support the phylogenetic data (Cox et al.,
2003). Figures 5 and 6 describe the correlation between
vaccine effectiveness and antigenic distances d1 and d2 from
the HI assay. A correlation is found in both ﬁgures. In the
season 1995–96 in Israel, the vaccine strain is A/Singapore/
6/86 (H1N1) and the dominant circulating strain is A/Texas/
36/91 (H1N1), between which the averaged d1 is 0.86. Since
the vaccine effectiveness is only 32.2%, its discrepancy to
the corresponding effectiveness 42.5% in the trend line is
much larger than 1 standard error of vaccine effectiveness.
Similarly, the same pair of vaccine strain and dominant cir-
culating strain introduces a data point further from the trend
line if d2 is used as the distance measure. We also notice that
two strains could be antigenically identical as measured with
HI assay but antigenically distinct as measured with pepitope.
As shown in Table II, in the season 1982–1983, the H1N1
vaccine strain A/Brazil/11/78 and dominant circulating strain
A/England/333/80 presented the antigenic distance measured
with HI assay d1 ¼ 0 and the sequence-based antigenic dis-
tance measure pepitope ¼ 0.083. The H3N2 vaccine strain and
dominant circulating strain showed identical d1 and d2 values
but distinct pepitope values in the seasons 1996–1997 and
2004–2005 (Gupta et al., 2006). Note that if pepitope is incor-
porated into the linear models shown in Figs 5 and 6, the R
2
value is increased. We ﬁt a linear model vaccine effective-
ness ¼ a þ b1pepitope þ b2d1 þ b3d2 þ 1 in which e is an
error term. The ﬁtted model is vaccine effectiveness ¼ 0.54–
2.179pepitope þ 0.068d1 þ 0.003d2 with R
2 ¼ 0.72.
Discussion
Veriﬁcation of the pepitope model
Originally the pepitope model was implemented for the H3N2
virus, where pepitope correlates with H3N2 vaccine
effectiveness with a signiﬁcantly larger R
2 than do pall-epitope
and psequence (Gupta et al., 2006; Sun et al., 2006). In the
case of H1N1, the advantage of pepitope over pall-epitope and
psequence is not as remarkable as for H3N2. We speculate that
antibodies against the H3N2 virus may bind to a small ﬁxed
region on the surface of H3 HA while antibodies against the
H1N1 virus may have multiple binding regions available. In
other words, we speculate that the dominant epitope in H3
HA may contribute substantially to the escape of the H3N2
virus from host antibodies, while escape mutations may
occur in the dominant epitope as well as perhaps the subdo-
minant epitopes of H1 HA. Our speculation comes from the
fact that the epitope region in H1N1 contains more amino
acid positions than does that in H3N2 (Deem and Pan 2009)
and the apparently less well deﬁned nature of the HINI
epitopes.
Two recent epidemiological studies (Centers for Disease
Control and Prevention (CDC), 2009a; Skowronski et al.,
Fig. 6 The correlation with R
2 ¼ 0.46 between vaccine effectiveness for ILI
and d2, the antigenic distance deﬁned by HI assay using ferret antisera. Data
from Table II. The d2 values were averaged if multiple HI assay
experimental data were found. The trend line quantiﬁes vaccine effectiveness
as a decreasing linear function of d2. Vaccine effectiveness ¼ –0.013
d2þ0.51.
Fig. 5 The correlation with R
2 ¼ 0.53 between vaccine effectiveness for ILI
and d1, the antigenic distance deﬁned by HI assay using ferret antisera. Data
from Table II. The d1 values were averaged if multiple HI assay
experimental data were found. The trend line quantiﬁes vaccine effectiveness
as a decreasing linear function of d1. Vaccine effectiveness ¼ –0.085
d1þ0.50.
Fig. 4 Vaccine effectiveness for ILI correlates with psequence with R
2 ¼
0.66. Data from Table II. The trend line quantiﬁes vaccine effectiveness as a
decreasing linear function of psequence. Vaccine effectiveness ¼ 27.37
psequenceþ0.54.
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the emergence of the H1N1 pandemic ﬂu in April 2009, the
2008–2009 ﬂu season was dominated by subtype H1N1
seasonal ﬂu. Both the dominant circulating strain and
the vaccine strain in the 2008–2009 season were A/
Brisbane/57/2007 (H1N1) (Centers for Disease Control and
Prevention (CDC), 2009d). The observed vaccine effective-
ness against seasonal ﬂu was 44% (95% conﬁdence interval,
CI: 33–59%) (Skowronski et al., 2010). The pepitope model
predicts the vaccine effectiveness as 53%, which falls into
the 95% CI of the reported vaccine effectiveness.
After April 2009, a new peak of inﬂuenza activity
emerged. The dominant circulating strain in this period was
the pandemic H1N1 strain A/California/7/2009 (Centers
for Disease Control and Prevention (CDC), 2009b,c). The
reported effectiveness of the 2008–2009 seasonal ﬂu vaccine
against the H1N1 pandemic ﬂu was 250 to 150%
(Skowronski et al., 2010) and 210% (95% CI: 243 to 15%)
(Centers for Disease Control and Prevention (CDC), 2009a).
The value of pepitope between A/California/7/2009 and
A/Brisbane/57/2007 is 0.77 with epitope B as the dominant
epitope. The vaccine effectiveness forecast by the pepitope
model is 239%, which agrees with the measured vaccine
effectiveness values.
Comparison of H3N2 and H1N1 vaccine effectiveness
and evolution rates
The pepitope model has been previously applied to the predic-
tion of H3N2 vaccine effectiveness (Gupta et al., 2006). The
H3N2 vaccine effectiveness with pepitope ¼ 0 is 44.6%, and
vaccine effectiveness is .0 for pepitope, 0.184 (Gupta et al.,
2006). Thus, H1N1 vaccines tend to have higher vaccine
effectiveness compared with H3N2 vaccines, as shown in
Fig. 2. The comparison between H3N2 and H1N1 vaccine
effectiveness [Fig. 2 versus Fig. 2 of (Gupta et al., 2006)]
illustrates that H1N1 vaccine has higher effectiveness than
the H3N2 vaccine as a function of pepitope. This observation
suggests that the host immune system is more effective at
recognizing and eliminating the H1N1 virus (pepitope ¼ 0),
and that humoral cross-immunity is stronger for H1 HA
(pepitope . 0). This observation also explains why an H3N2
epidemic is usually a more severe health threat than an
H1N1 epidemic. We propose that H1N1 has a longer history
of circulation in the human population, so human immune
system may recognize H1N1 more effectively, and this may
be the reason that under stronger immune pressure, the
H1N1 virus may have a higher degree of adaptation to the
human host. In the following discussion, we verify this
hypothesis by two facts. First, the H1N1 virus has a larger
antigenic diversity than does the H3N2 virus. Second, the
H1N1 virus presents higher evolutionary rate in the per
dominant season basis.
To compare the antigenic diversities of H1N1 and H3N2,
we downloaded from the NCBI database on 13 August 2009
all the amino acid sequences of H3 HA collected in the 18
years with H3N2 dominant circulating strains (Gupta et al.,
2006) and those of H1 HA collected in 7 years with H1N1
dominant circulating strains (Table II). Thus, 18 subsets of
H3N2 sequences and 7 subsets of H1N1 sequences were
formed. The centers of these subsets are the corresponding
vaccine strains in the same season of the circulating virus.
The radius of each subset is obtained by the calculation of
pepitope. First, the strains with the top 5% pepitope antigenic
distance measure to the center of each subset were selected,
to focus on the extent of viral evolution. Second, the pepitope
between these selected strains and the center were averaged
in each year as the radius. Third, the radii were averaged
over all the 18 years for H3N2 and over 7 years for H1N1.
That is, the average radius of the top 5% was calculated in
each year. As a result, the average H3N2 subset radius with
the vaccine strains as the centers is 0.211. The average H1N1
radius is 0.520 with the vaccine strains as the centers. This
difference between the H3N2 radius and the H1N1 radius is
signiﬁcant with the P-value 0.0118 using the Wilcoxon
rank-sum test. Consequently, the H1N1 virus has a larger
antigenic diversity in each season compared with the H3N2
virus, as shown in Fig. 7.
We also compared the evolutionary rates of H1N1 and
H3N2 because evolutionary rate of the virus is an index of
the selection pressure of the virus. The virus undergoes less
immune pressure in a non-dominant season and high
immune pressure in a dominant season. It has been noticed
that in H1 and H3 HA, the region outside epitopes presents
signiﬁcantly lower evolutionary rate than do the epitopes
(Ferguson et al., 2003; Deem and Pan, 2009). This phenom-
enon indicates that without immune pressure, the spon-
taneous evolutionary rates of both H1N1 and H3N2 are low.
Therefore, a higher evolutionary rate of one virus subtype in
a dominant season comes from the higher immune pressure
rather than neutral evolution, and we reject the alternative
scenario that the higher evolutionary rate causes a virus
subtype to be dominant in one season. So the evolutionary
rate per dominant season is a natural measure of the virus
evolution. Between 1983–1997, H3N2 was dominant in 8 of
15 years, and between 1977–2000, H1N1 was dominant in 5
of 24 years (Ferguson et al., 2003). Between 1980 and 2000,
the HA1 domain of H3 HA has a higher annual evolutionary
rate of 3.7   10
23 nucleotide substitution/site/year than does
the HA1 domain of H1 HA, which has the annual evolution-
ary rate of 1.8   10
23 nucleotide substitution/site/year
(Ferguson et al., 2003). Measured on a per dominant season
Fig. 7 The comparison between H3N2 (triangle up) and H1N1 (triangle
down) in regard to the antigenic diversity, the evolutionary rate between
1980 and 2000 (left), the evolutionary rate between 2000 and 2007 (right),
and the mutation rate on a short-time scale without ﬁxation. The antigenic
diversity is measured with pepitope, the unit of evolutionary rate is 10
–3
nucleotide substitution/site/year, and the unit of mutation rate is 10
–6
nucleotide substitution/site/day.
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297basis, however, the HA1 domain of H1 HA evolves faster in
its dominant season with the rate of 8.6   10
23 nucleotide
substitution/site/dominant season than does the H3 HA with
the rate of 6.9   10
23 nucleotide substitution/site/dominant
season. The difference is signiﬁcant with a P-value of
0.0008. Similarly, between 2000 and 2007, the HA1 domain
of H1 HA evolves faster in its dominant season with the rate
of 10.2   10
23 nucleotide substitution/site/dominant season
than does the H3 HA with the rate of 7.4   10
23 nucleotide
substitution/site/dominant season. The difference is signiﬁ-
cant with a P-value of 0.0005 (Zaraket et al., 2009). Here we
have divided the annual evolutionary rate by the proportion
of dominant years for both H1 and H3 HA. Even on a short-
time scale without ﬁxation, H1 HA shows a comparable or
higher mutation rate of 9.1   10
26 nucleotide substitution/
site/day than H3 HA of 4.2   10
26 nucleotide substitution/
site/day (P ¼ 0.26) (Nobusawa and Sato, 2006), probably
caused by the adaptation to the higher immune pressure, at
least for some strains. To make this last point, we have
assumed that the mutation rate of the HA gene is the same as
that of the NS gene. We assume that the same polymerase is
operating on these two genes, and so the mutation rates are
expected to be the same. The comparisons of evolutionary
rates and mutation rates between H3N2 and H1N1 are sum-
marized in Fig. 7.
The pepitope model as a supplement to HI assay
For both H1N1 (this paper) and H3N2 (Gupta et al., 2006),
the HI assay correlates less well with vaccine effectiveness
than does pepitope. Collection of HI assay data measuring
antigenic distance is also more time consuming and more
expensive compared with the pepitope model. Many hundreds
of strains are circulating and collected in an average ﬂu
season, thus an HI table with tens of thousands of entries
needs to be built to assess the antigenic distance between
each pair of strains. With the high-throughput sequencing
technology generating HA sequence data, such antigenic dis-
tances are easily measured with the sequence-based antigenic
distance measure pepitope, which correlates to a greater degree
with vaccine effectiveness than do the HI data.
The pepitope model is developed to provide researchers and
health authorities with a new tool to quantify antigenic dis-
tance and design the vaccine. We do not suggest that pepitope
should substitute for the current HI assay, but rather suggest
that pepitope serves as an additional assessment when select-
ing vaccine strains. Using pepitope to supplement to HI assay
data may allow researchers and health authorities to more
precisely quantify the antigenic distance between dominant
circulating strains and candidate vaccine strains. The adop-
tion of the pepitope theory may also allow researchers to mini-
mize the cost and the number of ferret experiments and to
correct HI assay data in some situations.
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